Infectious Complications During Early Treatment of Childhood Acute Lymphoblastic Leukemia-A Comparison Between the ALLTogether and NOPHO ALL-2008 Protocols.

IF 2.3 3区 医学 Q2 HEMATOLOGY
Hannah van Bunningen, Johannes Fermér, Arja Harila, Susanna Ranta, Isabella Donnér, Anne Wretman, Hartmut Vogt, Anna Sällfors Holmqvist, Anders Valind, Ludvig Henriksson, Jonas Abrahamsson, Magnus Borssén, Anna Nilsson, Mats Heyman
{"title":"Infectious Complications During Early Treatment of Childhood Acute Lymphoblastic Leukemia-A Comparison Between the ALLTogether and NOPHO ALL-2008 Protocols.","authors":"Hannah van Bunningen, Johannes Fermér, Arja Harila, Susanna Ranta, Isabella Donnér, Anne Wretman, Hartmut Vogt, Anna Sällfors Holmqvist, Anders Valind, Ludvig Henriksson, Jonas Abrahamsson, Magnus Borssén, Anna Nilsson, Mats Heyman","doi":"10.1002/pbc.32120","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Infection remains the most common treatment-related toxicity of childhood ALL, emphasizing the need to identify patients at risk and to tailor treatment strategies accordingly.</p><p><strong>Aims: </strong>The primary aim was to compare infectious toxicity during early treatment for childhood ALL following the ALLTogether and NOPHO ALL-2008 (ALL-2008) protocols, and second, to identify risk factors for infectious toxicity.</p><p><strong>Methods: </strong>A national retrospective matched cohort study was conducted, including 345 patients aged 1-17 years diagnosed with ALL and treated in Sweden according to the ALLTogether or ALL-2008 protocols. Nonparametric tests were used to compare infectious outcomes between protocols, and regression modeling was used to identify risk factors of the infectious outcomes.</p><p><strong>Results: </strong>Treatment following ALL-2008 showed higher infectious toxicity during induction, whereas treatment following ALLTogether showed increased infectious toxicity during consolidation 1. Overall, treatment according to ALL-2008 was associated with a higher incidence of infections. Anthracycline use and young age (1-9 years) were associated with both higher infectious incidence and more severe infectious complications. Dexamethasone was associated with both lower incidence and lower severity of infectious complications as compared to prednisone.</p><p><strong>Conclusions: </strong>A notable shift in the timing of infectious toxicity was observed between the two treatment protocols. Risk factors for infectious toxicity during early treatment include anthracycline use and young age. Dexamethasone as an induction steroid was associated with lower infectious burden, although its effect is difficult to isolate from the simultaneous anthracycline effect. The findings suggest that treatment composition plays a central role in determining both the extent and timing of infectious complications.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":" ","pages":"e32120"},"PeriodicalIF":2.3000,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Blood & Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pbc.32120","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Infection remains the most common treatment-related toxicity of childhood ALL, emphasizing the need to identify patients at risk and to tailor treatment strategies accordingly.

Aims: The primary aim was to compare infectious toxicity during early treatment for childhood ALL following the ALLTogether and NOPHO ALL-2008 (ALL-2008) protocols, and second, to identify risk factors for infectious toxicity.

Methods: A national retrospective matched cohort study was conducted, including 345 patients aged 1-17 years diagnosed with ALL and treated in Sweden according to the ALLTogether or ALL-2008 protocols. Nonparametric tests were used to compare infectious outcomes between protocols, and regression modeling was used to identify risk factors of the infectious outcomes.

Results: Treatment following ALL-2008 showed higher infectious toxicity during induction, whereas treatment following ALLTogether showed increased infectious toxicity during consolidation 1. Overall, treatment according to ALL-2008 was associated with a higher incidence of infections. Anthracycline use and young age (1-9 years) were associated with both higher infectious incidence and more severe infectious complications. Dexamethasone was associated with both lower incidence and lower severity of infectious complications as compared to prednisone.

Conclusions: A notable shift in the timing of infectious toxicity was observed between the two treatment protocols. Risk factors for infectious toxicity during early treatment include anthracycline use and young age. Dexamethasone as an induction steroid was associated with lower infectious burden, although its effect is difficult to isolate from the simultaneous anthracycline effect. The findings suggest that treatment composition plays a central role in determining both the extent and timing of infectious complications.

儿童急性淋巴细胞白血病早期治疗中的感染并发症——ALLTogether和NOPHO ALL-2008方案的比较
感染仍然是儿童ALL最常见的治疗相关毒性,强调需要识别处于危险中的患者并相应地调整治疗策略。目的:主要目的是比较ALLTogether和NOPHO ALL-2008 (ALL-2008)方案下儿童ALL早期治疗期间的感染性毒性,其次,确定感染性毒性的危险因素。方法:进行了一项全国性的回顾性匹配队列研究,包括345名1-17岁的ALL患者,他们被诊断为ALL,并在瑞典根据ALL- together或ALL-2008方案进行治疗。采用非参数检验比较不同方案的感染结局,并采用回归模型确定感染结局的危险因素。结果:ALL-2008治疗在诱导期表现出更高的感染毒性,而all - together治疗在巩固期表现出更高的感染毒性1。总体而言,根据ALL-2008进行的治疗与较高的感染发生率相关。蒽环类药物的使用和年幼(1-9岁)与较高的感染发生率和更严重的感染并发症相关。与强的松相比,地塞米松感染并发症的发生率和严重程度都较低。结论:在两种治疗方案之间观察到感染性毒性发生时间的显著变化。早期治疗期间感染性毒性的危险因素包括蒽环类药物的使用和年轻。地塞米松作为一种诱导类固醇与较低的感染负荷相关,尽管其作用很难从同时发生的蒽环类药物作用中分离出来。研究结果表明,治疗组合在决定感染并发症的程度和时间方面起着核心作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pediatric Blood & Cancer
Pediatric Blood & Cancer 医学-小儿科
CiteScore
4.90
自引率
9.40%
发文量
546
审稿时长
1.5 months
期刊介绍: Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信